No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MEDP240517P360000
- 0.52
- 0.000.00%
15min DelayClose May 14 15:59 ET
0.52High0.52Low
0.52Open0.52Pre Close1 Volume85 Open Interest360.00Strike Price52.00Turnover66.68%IV-9.80%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.52Time Value100Contract SizeAmericanOptions Type-0.0487Delta0.0040Gamma766.38Leverage Ratio-0.3296Theta-0.0017Rho-37.36Eff Leverage0.0379Vega
Intraday
- 5D
- 1D
News
Medpace(MEDP.US) 10% Shareholder Sells US$2 Million in Common Stock
$Medpace(MEDP.US)$ 10% Shareholder Troendle August J. sold 4,956 shares of common stock on May 10, 2024 at an average price of $402.89 for a total value of $2 million.Source: Announcement What is stat
Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing
August J. Troendle, 10% Owner, Director, CEO, on May 10, 2024, sold 4,956 shares in Medpace Holdings (MEDP) for $1,996,723. Following the Form 4 filing with the SEC, Troendle has control over a total
Here's How Much You Would Have Made Owning Medpace Hldgs Stock In The Last 5 Years
Medpace Hldgs (NASDAQ:MEDP) has outperformed the market over the past 5 years by 35.09% on an annualized basis producing an average annual return of 48.03%. Currently, Medpace Hldgs has a market capit
Zacks.com Featured Highlights Medpace, American Axle, Diebold Nixdorf, Euronet and Omnicom
5 Stocks With Upgraded Broker Ratings Worth Investing in Now
Medpace(MEDP.US) 10% Shareholder Sells US$3.31 Million in Common Stock
$Medpace(MEDP.US)$ 10% Shareholder Troendle August J. sold 8,268 shares of common stock on May 8, 9, 2024 at an average price of $400.41 for a total value of $3.31 million.Source: Announcement What is
Comments
Investors expect Medpace Holdings to outperform the market, hence its high P/E ratio. Strong future growth anticipation makes investors pay more for the stock, supporting the share price.
The Price Is Right For Medpace Holdings, Inc. (NASDAQ:MEDP) 1
Medpace Holdings' robust conversion of profit to free cash flow is promising. Its underlying earnings potential may even surpass the statutory profit. Its earnings per share have seen a remarkable growth over the past three years.
1
Medpace Holdings' market sentiment remains steady, mirroring EPS growth. The stock's recent performance shows improvement, with a 90% shareholder return over the last year, surpassing the five-year TSR of 41% per year. The strong share price momentum suggests a closer look at the stock may be worthwhile.
Medpace's high P/E is backed by its forecast growth being higher than the wider market. Investors are quite confident in the company's future earnings and seem willing to pay more for the stock, suggesting a bullish outlook.
Insider selling at current price (US$274) is less worrying, but there were no purchases over the past year to boost confidence. A high level of insider ownership often implies interests of all shareholders are considered, though recent history of share sales triggers some hesitation.
Read more